DUBLIN, Ireland I January 04, 2023 I Horizon Therapeutics plc (Nasdaq: HZNP) today announced the first patient has enrolled in a Phase 2, randomized, placebo-controlled trial to evaluate its development-stage medicine daxdilimab, a potentially first-in-class, fully human monoclonal antibody targeting anti-ILT7 depletes certain dendritic cells to treat people with moderate-to-severe primary discoid lupus erythematosus (DLE).
DLE is a rare, chronic, inflammatory skin condition characterized by lesions that result in scarring, irreversible hair loss and skin discoloration with no approved therapies. The localized form of primary DLE is characterized by limited cutaneous involvement of the head and scalp and usually accounts for 70 percent of primary DLE. The generalized form is characterized beyond this and includes the head-body area and usually accounts for about 30 percent of primary DLE.1 In the United States, approximately 30,000 patients with DLE are appropriate for treatment with novel therapies, including biologics.2 Primary DLE incidence rates are approximately four times higher among women compared with men and the disease has a higher prevalence among non-Latino Black and Latino populations.3
“DLE is one of the most challenging scarring skin diseases because there is no curative treatment. It causes round, inflammatory lesions that favor the scalp, face and ears and is associated with a diminished quality of life in patients,” said Benjamin Chong, M.D., associate professor, department of dermatology, University of Texas Southwestern Medical Center. “There is a tremendous unmet medical need for safe treatments for DLE. This trial will help evaluate the potential of daxdilimab to meet this need.”
Horizon expects to enroll approximately 100 participants in the trial. The primary endpoint is the mean change in Cutaneous Lupus Erythematosus Disease Area and Severity Index-Activity (CLASI-A) score from baseline to Week 24. This endpoint is used to measure activity in inflammatory lupus skin disease and ranges from 0 to 70 with higher scores indicating more active and skin damaging disease.4
Key inclusion criteria include a diagnosis of moderate-to-severe DLE for more than six months prior to screening supported by a biopsy and/or a clinical feature score of ≥ 7 on the DLE Classification Criteria (DLECC) scale. This score is used to specifically validate and classify DLE across several clinical variables including atrophic scarring, disease location on the body and dyspigmentation.5
“Plasmacytoid dendritic cells, or pDCs, are reported to be abundant in DLE skin lesions while interferon levels are elevated and daxdilimab has been shown to deplete pDCs,” said Theresa Podrebarac, M.D., M.Sc., senior vice president, clinical development, Horizon. “DLE can lead to alopecia or permanent hair loss and skin dyspigmentation. Daxdilimab is also being investigated in other autoimmune conditions that are driven by high levels of interferon, including alopecia areata, dermatomyositis, lupus nephritis and systemic lupus erythematosus.”
About Daxdilimab
Daxdilimab is an anti-ILT7 human monoclonal antibody that depletes certain dendritic cells. Depleting these cells may interrupt the cycle of inflammation that causes tissue damage in a variety of autoimmune conditions. Horizon is also investigating daxdilimab in systemic lupus erythematosus and alopecia areata and plans to investigate it in dermatomyositis and lupus nephritis.
About Horizon
Horizon is a global biotechnology company focused on the discovery, development and commercialization of medicines that address critical needs for people impacted by rare, autoimmune and severe inflammatory diseases. Our pipeline is purposeful: We apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives. For more information on how we go to incredible lengths to impact lives, visit www.horizontherapeutics.com and follow us on Twitter, LinkedIn, Instagram and Facebook.
References
- Fabbri P, Cardinali C, Giomi B, Caproni M. Cutaneous lupus erythematosus: diagnosis and management. Am J Clin Dermatol. 2003;4(7):449-65.
- Durosaro O, Davis MD, Reed KB, Rohlinger AL. Incidence of cutaneous lupus erythematosus, 1965-2005: a population-based study. Arch Dermatol. 2009;145(3):249-253.
- Izmirly P, Buyon J, Belmont HM, et al. Population-based prevalence and incidence estimates of primary discoid lupus erythematosus from the Manhattan Lupus Surveillance Program [published correction appears in Lupus Sci Med. 2019 Nov 14;6(1):e000344corr1]. Lupus Sci Med. 2019;6(1):e000344.
- Chakka S, Krain RL, Concha JSS, Chong BF, Merola JF, Werth VP. The CLASI, a validated tool for the evaluation of skin disease in lupus erythematosus: a narrative review. Ann Transl Med. 2021;9(5):431.
- Guo LN, Perez-Chada LM, Borucki R, et al. Development of a working core outcome set for cutaneous lupus erythematosus: a practical approach to an urgent unmet need. Lupus Science & Medicine 2021;8:e000529.
SOURCE: Horizon Therapeutics
Post Views: 404
DUBLIN, Ireland I January 04, 2023 I Horizon Therapeutics plc (Nasdaq: HZNP) today announced the first patient has enrolled in a Phase 2, randomized, placebo-controlled trial to evaluate its development-stage medicine daxdilimab, a potentially first-in-class, fully human monoclonal antibody targeting anti-ILT7 depletes certain dendritic cells to treat people with moderate-to-severe primary discoid lupus erythematosus (DLE).
DLE is a rare, chronic, inflammatory skin condition characterized by lesions that result in scarring, irreversible hair loss and skin discoloration with no approved therapies. The localized form of primary DLE is characterized by limited cutaneous involvement of the head and scalp and usually accounts for 70 percent of primary DLE. The generalized form is characterized beyond this and includes the head-body area and usually accounts for about 30 percent of primary DLE.1 In the United States, approximately 30,000 patients with DLE are appropriate for treatment with novel therapies, including biologics.2 Primary DLE incidence rates are approximately four times higher among women compared with men and the disease has a higher prevalence among non-Latino Black and Latino populations.3
“DLE is one of the most challenging scarring skin diseases because there is no curative treatment. It causes round, inflammatory lesions that favor the scalp, face and ears and is associated with a diminished quality of life in patients,” said Benjamin Chong, M.D., associate professor, department of dermatology, University of Texas Southwestern Medical Center. “There is a tremendous unmet medical need for safe treatments for DLE. This trial will help evaluate the potential of daxdilimab to meet this need.”
Horizon expects to enroll approximately 100 participants in the trial. The primary endpoint is the mean change in Cutaneous Lupus Erythematosus Disease Area and Severity Index-Activity (CLASI-A) score from baseline to Week 24. This endpoint is used to measure activity in inflammatory lupus skin disease and ranges from 0 to 70 with higher scores indicating more active and skin damaging disease.4
Key inclusion criteria include a diagnosis of moderate-to-severe DLE for more than six months prior to screening supported by a biopsy and/or a clinical feature score of ≥ 7 on the DLE Classification Criteria (DLECC) scale. This score is used to specifically validate and classify DLE across several clinical variables including atrophic scarring, disease location on the body and dyspigmentation.5
“Plasmacytoid dendritic cells, or pDCs, are reported to be abundant in DLE skin lesions while interferon levels are elevated and daxdilimab has been shown to deplete pDCs,” said Theresa Podrebarac, M.D., M.Sc., senior vice president, clinical development, Horizon. “DLE can lead to alopecia or permanent hair loss and skin dyspigmentation. Daxdilimab is also being investigated in other autoimmune conditions that are driven by high levels of interferon, including alopecia areata, dermatomyositis, lupus nephritis and systemic lupus erythematosus.”
About Daxdilimab
Daxdilimab is an anti-ILT7 human monoclonal antibody that depletes certain dendritic cells. Depleting these cells may interrupt the cycle of inflammation that causes tissue damage in a variety of autoimmune conditions. Horizon is also investigating daxdilimab in systemic lupus erythematosus and alopecia areata and plans to investigate it in dermatomyositis and lupus nephritis.
About Horizon
Horizon is a global biotechnology company focused on the discovery, development and commercialization of medicines that address critical needs for people impacted by rare, autoimmune and severe inflammatory diseases. Our pipeline is purposeful: We apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives. For more information on how we go to incredible lengths to impact lives, visit www.horizontherapeutics.com and follow us on Twitter, LinkedIn, Instagram and Facebook.
References
- Fabbri P, Cardinali C, Giomi B, Caproni M. Cutaneous lupus erythematosus: diagnosis and management. Am J Clin Dermatol. 2003;4(7):449-65.
- Durosaro O, Davis MD, Reed KB, Rohlinger AL. Incidence of cutaneous lupus erythematosus, 1965-2005: a population-based study. Arch Dermatol. 2009;145(3):249-253.
- Izmirly P, Buyon J, Belmont HM, et al. Population-based prevalence and incidence estimates of primary discoid lupus erythematosus from the Manhattan Lupus Surveillance Program [published correction appears in Lupus Sci Med. 2019 Nov 14;6(1):e000344corr1]. Lupus Sci Med. 2019;6(1):e000344.
- Chakka S, Krain RL, Concha JSS, Chong BF, Merola JF, Werth VP. The CLASI, a validated tool for the evaluation of skin disease in lupus erythematosus: a narrative review. Ann Transl Med. 2021;9(5):431.
- Guo LN, Perez-Chada LM, Borucki R, et al. Development of a working core outcome set for cutaneous lupus erythematosus: a practical approach to an urgent unmet need. Lupus Science & Medicine 2021;8:e000529.
SOURCE: Horizon Therapeutics
Post Views: 404
